<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04231617</url>
  </required_header>
  <id_info>
    <org_study_id>H-19065735</org_study_id>
    <nct_id>NCT04231617</nct_id>
  </id_info>
  <brief_title>The Hemodynamic Effects of CGRP After Glibenclamide Administration in Healthy Volunteers</brief_title>
  <official_title>The Hemodynamic Effects of CGRP After Glibenclamide Administration in a Randomized Double-blind Cross-over Placebo-controlled Study With Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Headache Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danish Headache Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the hemodynamic effects of CGRP after glibenclamide administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      20 healthy participants will randomly be allocated to receive CGRP infusion followed by
      glibenclamide or placebo on two different days.

      The aim of the study is to investigate the vascular effect of CGRP after glibenclamide
      administration.

      Repeated measurements covering the arteria radialis (RA), superficiel temporal artery (STA)
      and middle cerebral artery (MCA) before and after glibenclamide/placebo administration and
      CGRP infusion.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, cross-over, placebo-controlled design in healthy volunteers.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the arterial radialis (RA), superficiel temporal artery (STA) and middle cerebral artery (MCA)</measure>
    <time_frame>Time of measurements is baseline and repeatedly every 20 min for 240 min.</time_frame>
    <description>Repeated measurements covering the diameter of RA , STA and MCA before and after glibenclamide/placebo administration and CGRP infusion measured by centimeter (cm)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Headache</measure>
    <time_frame>Time of headache measurements is from before (-20 min) and after (12 hours) glibenclamide/placebo administration.</time_frame>
    <description>Headache intensity will be recorded by numerical rating scale (NRS) from 0 to 10 (0, no headache; 1, a feeling of pressure; 10, worst imaginable headache).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hemodynamics of Cranial Arteries</condition>
  <condition>Headache</condition>
  <condition>Cerebral Blood Flow</condition>
  <arm_group>
    <arm_group_label>CGRP and glibenclamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will recieve CGRP infusion after glibenclamide/placebo administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CGRP and placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will recieve CGRP infusion after glibenclamide/placebo administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glibenclamide</intervention_name>
    <description>Oral administration of glibenclamide or placebo. To investigate the role of CGRP on cranial arteries in healthy volunteers after glibenclamide/placebo administration .</description>
    <arm_group_label>CGRP and glibenclamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CGRP infusion</intervention_name>
    <description>CGRP infusion</description>
    <arm_group_label>CGRP and glibenclamide</arm_group_label>
    <arm_group_label>CGRP and placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>CGRP and placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers of both sexes.

          -  18-60 years.

          -  50-100 kg.

          -  Women of childbearing potential must use adequate contraception

        Exclusion Criteria:

          -  A history of serious somatic disease

          -  Migraine or any other type of headache (except episodic tension-type headache less
             than once a month)

          -  Daily intake of any medication except contraceptives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mohammad M Al-Karagholi</last_name>
    <phone>31191647</phone>
    <email>mahdi.alkaragholi@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Danish headache center</name>
      <address>
        <city>Glostrup</city>
        <state>Copenhagen</state>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammad M Al-Karagholi</last_name>
      <phone>31191647</phone>
      <email>mahdi.alkaragholi@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mohammad Al-Mahdi Al-Karagholi</name>
      <address>
        <city>KÃ¸benhavn S</city>
        <state>Danmark</state>
        <zip>2300</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammad M Al-Karagholi</last_name>
      <phone>31191647</phone>
      <email>mahdi.alkaragholi@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 14, 2020</study_first_submitted>
  <study_first_submitted_qc>January 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish Headache Center</investigator_affiliation>
    <investigator_full_name>Mohammad Al-Mahdi Al-Karagholi</investigator_full_name>
    <investigator_title>MD, PhD student, Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glyburide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

